{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:52:50Z","timestamp":1794293570639,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473346"],"award-info":[{"award-number":["82473346"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272789"],"award-info":[{"award-number":["82272789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science &Technology Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41591-025-03600-2","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:03:51Z","timestamp":1741845831000},"page":"1949-1957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1173-8441","authenticated-orcid":false,"given":"Yuxiang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-0175","authenticated-orcid":false,"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-0419","authenticated-orcid":false,"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-9064","authenticated-orcid":false,"given":"David","family":"Sommerhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8415-6001","authenticated-orcid":false,"given":"Wei","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5961-7724","authenticated-orcid":false,"given":"Tongtong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-0761","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-3888","authenticated-orcid":false,"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"3600_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao, B. et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J. Hematol. Oncol. 15, 153 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"3600_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0540-1","volume":"7","author":"D Carvajal-Hausdorf","year":"2019","unstructured":"Carvajal-Hausdorf, D. et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC). J. Immunother. Cancer 7, 65 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"3600_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0752-4","volume":"7","author":"YQ Wang","year":"2019","unstructured":"Wang, Y. Q. et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J. Immunother. Cancer 7, 298 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"3600_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","volume":"10","author":"R Pulido","year":"2024","unstructured":"Pulido, R., L\u00f3pez, J. I. & Nunes-Xavier, C. E. B7-H3: a robust target for immunotherapy in prostate cancer. Trends Cancer 10, 584\u2013587 (2024).","journal-title":"Trends Cancer"},{"key":"3600_CR5","doi-asserted-by":"publisher","first-page":"16077","DOI":"10.3390\/ijms232416077","volume":"23","author":"U Malapelle","year":"2022","unstructured":"Malapelle, U. et al. B7-H3\/CD276 inhibitors: is there room for the treatment of metastatic non-small cell lung cancer? Int. J. Mol. Sci. 23, 16077 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"3600_CR6","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.3390\/ijms25073976","volume":"25","author":"V Joshi","year":"2024","unstructured":"Joshi, V. et al. B7-H3 expression in breast cancer and brain metastasis. Int. J. Mol. Sci. 25, 3976 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"3600_CR7","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s00432-022-04244-2","volume":"149","author":"M Borgmann","year":"2023","unstructured":"Borgmann, M. et al. The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 149, 3383\u20133393 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"3600_CR8","doi-asserted-by":"publisher","first-page":"1408051","DOI":"10.3389\/fonc.2024.1408051","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu, S., Hu, C., Hui, K. & Jiang, X. Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature. Front. Oncol. 14, 1408051 (2024).","journal-title":"Front. Oncol."},{"key":"3600_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu, A. A. et al. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol. Cancer 22, 43 (2023).","journal-title":"Mol. Cancer"},{"key":"3600_CR10","doi-asserted-by":"publisher","first-page":"188783","DOI":"10.1016\/j.bbcan.2022.188783","volume":"1877","author":"RK Kanchan","year":"2022","unstructured":"Kanchan, R. K., Doss, D., Khan, P., Nasser, M. W. & Mahapatra, S. To kill a cancer: targeting the immune inhibitory checkpoint molecule, B7-H3. Biochim. Biophys. Acta Rev. Cancer 1877, 188783 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"3600_CR11","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/JCO.20.01974","volume":"38","author":"S Modak","year":"2020","unstructured":"Modak, S. et al. B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study. J. Clin. Oncol. 38, 4283\u20134291 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR12","doi-asserted-by":"publisher","first-page":"LB061","DOI":"10.1158\/1538-7445.AM2022-LB061","volume":"82","author":"R Gorlick","year":"2022","unstructured":"Gorlick, R. et al. Evaluation of the in vivo efficacy of the B7-H3 targeting antibody-drug conjugate (ADC) DS7300a: a report from the Pediatric Preclinical In Vivo Resting (PIVOT) program. Cancer Res. 82, LB061 (2022).","journal-title":"Cancer Res."},{"key":"3600_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","volume":"91","author":"C Gronbeck","year":"2024","unstructured":"Gronbeck, C., Hadfield, M. J. & Grant-Kels, J. M. Dermatologic toxicities of antibody-drug conjugates. J. Am. Acad. Dermatol. 91, 1177\u20131188 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3600_CR14","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1002\/mco2.671","volume":"5","author":"J He","year":"2024","unstructured":"He, J., Zeng, X., Wang, C., Wang, E. & Li, Y. Antibody\u2013drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm 5, e671 (2024).","journal-title":"MedComm"},{"key":"3600_CR15","doi-asserted-by":"publisher","first-page":"S481","DOI":"10.1016\/j.annonc.2023.09.1876","volume":"34","author":"MR Patel","year":"2023","unstructured":"Patel, M. R. et al. 690P ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: updated clinical and biomarker results from a phase I\/II study. Ann. Oncol. 34, S481\u2013S482 (2023).","journal-title":"Ann. Oncol."},{"key":"3600_CR16","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1200\/JCO.2024.42.16_suppl.8093","volume":"42","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. ARTEMIS-001: data from a phase 1a\/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). J. Clin. Oncol. 42, 8093 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR17","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2024.42.16_suppl.3012","volume":"42","author":"L Shen","year":"2024","unstructured":"Shen, L. et al. Results of a phase 1\/2 study of MHB088C: a novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. J. Clin. Oncol. 42, 3012 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR18","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","volume":"41","author":"BA Carneiro","year":"2023","unstructured":"Carneiro, B. A. et al. Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: dose expansion results. J. Clin. Oncol. 41, 3027 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR19","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1158\/1538-7445.AM2023-6304","volume":"83","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors. Cancer Res. 83, 6304 (2023).","journal-title":"Cancer Res."},{"key":"3600_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/1538-7445.AM2023-596","volume":"83","author":"J Cai","year":"2023","unstructured":"Cai, J., Song, S., Zong, Q., Liu, Q. & Xu, J. Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments. Cancer Res. 83, 596 (2023).","journal-title":"Cancer Res."},{"key":"3600_CR21","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1538-7445.AM2024-4702","volume":"84","author":"T Xue","year":"2024","unstructured":"Xue, T. et al. MediLink\u2019s TMALIN ADC linker technology: tumor microenvironment specific extracellular and intracellular double cleavage mechanism for better efficacy and expanded target space. Cancer Res. 84, 4702 (2024).","journal-title":"Cancer Res."},{"key":"3600_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 25, 901\u2013911 (2024).","journal-title":"Lancet Oncol."},{"key":"3600_CR23","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jtho.2024.09.033","volume":"19","author":"CM Rudin","year":"2024","unstructured":"Rudin, C. M. Ifinatamab deruxtecan (l-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of lDeate-Lung01. J. Thorac. Oncol. 19, S15\u2013S16 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"3600_CR24","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","volume":"25","author":"JR Eckardt","year":"2007","unstructured":"Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086\u20132092 (2007).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo, J. et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 21, 645\u2013654 (2020).","journal-title":"Lancet Oncol."},{"key":"3600_CR26","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn, M. J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3600_CR27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/annonc\/mdq425","volume":"22","author":"J Ngeow","year":"2011","unstructured":"Ngeow, J. et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann. Oncol. 22, 718\u2013722 (2011).","journal-title":"Ann. Oncol."},{"key":"3600_CR28","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu, C. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J. Clin. Oncol. 35, 4050\u20134056 (2017).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/2326-6066.CIR-22-0374","volume":"11","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. EBV-upregulated B7-H3 inhibits NK cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression. Cancer Immunol. Res. 11, 830\u2013846 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"3600_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10902-w","volume":"10","author":"S Hong","year":"2019","unstructured":"Hong, S. et al. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat. Commun. 10, 3108 (2019).","journal-title":"Nat. Commun."},{"key":"3600_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610\u2013621 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3600_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem, E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 24, 744\u2013756 (2023).","journal-title":"Lancet Oncol."},{"key":"3600_CR33","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto, K. et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J. Clin. Oncol. 41, 4852\u20134863 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3600_CR34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cpt.2291","volume":"110","author":"O Yin","year":"2021","unstructured":"Yin, O. et al. Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan. Clin. Pharmacol. Ther. 110, 986\u2013996 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3600_CR35","unstructured":"Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs Biologics. Guidance for Industry (US Food & Drug Administration, 2022); https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03600-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:10:44Z","timestamp":1776856244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03600-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Z. reports receiving research support from AstraZeneca, Akeso Biopharma, Bristol Myers Squibb, Chia Tai Tianqing Pharmaceutical Group, Junshi Pharmaceuticals, QiLu Pharmaceutical and Pfizer. S.C., X.Z., W.L., J.C. and T.X. are employees of MediLink Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}